DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

848 Stewart RB, Bardy GH, Greene HL. Wide complex tachycardia:
Misdiagnosis and outcome after emergent therapy. Ann Intern
Med, 1986, 104:766–771.
Sung RJ, Shapiro WA, Shen EN, et al. Effects of verapamil on
ventricular tachycardias possibly caused by reentry, automaticity,
and triggered activity. J Clin Invest, 1983, 72:350–360.
Task Force of the Working Group on Arrhythmias of the
European Society of Cardiology. The Sicilian gambit: A new
approach to the classification of antiarrhythmic drugs based
on their actions on arrhythmogenic mechanisms. Circulation,
1991, 84:1831–1851.
Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al.
Dofetilide in patients with congestive heart failure and left ventricular
dysfunction. Danish Investigations of Arrhythmia and
Mortality on Dofetilide Study Group. N Engl J Med, 1999,
341:857–865.
Tseng GN, Hoffman BF. Two components of transient outward
current in canine ventricular myocytes. Circ Res, 1989, 64:
633–647.
Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de
pointes with magnesium sulfate. Circulation, 1988, 77:
392–397.
Vaughan Williams EM. Classifying antiarrhythmic actions: By
facts or speculation. J Clin Pharmacol, 1992, 32:964–977.
SECTION III
Vinogradova TM, Lakatta EG. Regulation of basal and reserve
cardiac pacemaker function by interactions of cAMP-mediated
PKA-dependent Ca 2+ cycling with surface membrane channels.
J Mol Cell Cardiol, 2009, 47:456–474.
Wang ZG, Pelletier LC, Talajic M, Nattel S. Effects of flecainide
and quinidine on human atrial action potentials: Role of ratedependence
and comparison with guinea pig, rabbit, and dog
tissues. Circulation, 1990, 82:274–283.
Watanabe H, Chopra N, Laver D, et al. Flecainide prevents catecholaminergic
polymorphic ventricular tachycardia in mice
and humans. Nat Med, 2009, 15:380–383.
Weiss JN, Nademanee K, Stevenson WG, Singh B. Ventricular
arrhythmias in ischemic heart disease. Ann Intern Med, 1991,
114:784–797.
Wenckebach KF. Cinchona derivates in the treatment of heart
disorders. JAMA, 1923, 81:472–474.
Woods KL, Fletcher S. Long-term outcome after intravenous
magnesium sulphate in suspected acute myocardial infarction:
The second Leicester Intravenous Magnesium Intervention
Trial (LIMIT-2). Lancet, 1994, 343:816–819.
Woosley RL, Drayer DE, Reidenberg MM, et al. Effect of acetylator
phenotype on the rate at which procainamide induces
antinuclear antibodies and the lupus syndrome. N Engl J Med,
1978, 298:1157–1159.
MODULATION OF CARDIOVASCULAR FUNCTION